Global /United States /Healthcare /Biotechnology /FBRX

Forte Biosciences, Inc.

FBRX

• NASDAQ: FBRX • Delayed

28.03USD 6.2%

As of 14 June 2026, Forte Biosciences, Inc. has a market cap of $686.12M USD, ranking #13063 globally and #2431 in the United States. It ranks #1182 in the Healthcare sector, and #220 in the Biotechnology industry.

Global Rank

13063

Country Rank

2431

Sector Rank

1182

Industry Rank

220

Key Stats

Market Cap

$686.12MUSD

Enterprise Value

$594.97MUSD

EBITDA (TTM)

-$70.59MUSD

Net Income (TTM)

-$69.38MUSD

PB Ratio

7.7

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Paul A. Wagner open_in_new

Employees

Website

fortebiorx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
6.2%	-6%	9.9%	-6.1%	108%	2.8%	294%	4.8%	-97%

News

FBRX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	FBRX Forte Biosciences Inc Ordinary Shares ISIN: US34962G2084 Shares Out.: Shares Outstanding: 20.479M¹ Shares Float: 17.845M² TV: TradingView: NASDAQ: FBRX SA: Stock Analysis: NASDAQ: FBRX YF: Yahoo Finance: FBRX GF: Google Finance: NASDAQ: FBRX NQ: NASDAQ: FBRX BA: Barron's: FBRX MS: Morningstar: XNAS: FBRX	28.03 USD	TV: TradingView: NASDAQ: FBRX SA: Stock Analysis: NASDAQ: FBRX YF: Yahoo Finance: FBRX GF: Google Finance: NASDAQ: FBRX NQ: NASDAQ: FBRX BA: Barron's: FBRX MS: Morningstar: XNAS: FBRX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Forte Biosciences, Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 26K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 23K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 4K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 4K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 4K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 3K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 7K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 6K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 6K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 6K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 4K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 4K%	-	Germany

chevron_leftBack